A versatile adeno-associated virus vector producer cell line method for scalable vector production of different serotypes

Human Gene Therapy

Volumn 22, Issue 5, 2011, Pages 613-624

  Yuan, Zhenhua ^a   Qiao, Chunping ^a   Hu, Peiqi ^a   Li, Juan ^a   Xiao, Xiao ^a  

^a University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PARVOVIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL GROWTH; CELL LINE; CONTROLLED STUDY; GENE AMPLIFICATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IN VITRO GENE TRANSFER; IN VIVO GENE TRANSFER; MOLECULAR CLONING; MOUSE; NONHUMAN; PLASMID; SEROTYPE; VECTOR CONTROL;

BIOTECHNOLOGY; CELL CULTURE TECHNIQUES; CELL LINE; CLONING, MOLECULAR; DEPENDOVIRUS; GENETIC VECTORS; HUMANS; PLASMIDS; TRANSFECTION;

ADENO-ASSOCIATED VIRUS; ADENOVIRIDAE; ANIMALIA;

EID: 79955387179     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.241     Document Type: Article

References (45)

1. Asokan, A., Conway, J.C., Phillips, J.L., et al. (2010). Re-engineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nat. Biotechnol. 28, 79-82.
2. Ayuso, E., Mingozzi, F., Montane, J., et al. (2010). High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 17, 503-510.
3. Brantly, M.L., Chulay, J.D., Wang, L., et al. (2009). Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. U. S. A. 106, 16363-16368.
4. Campeau, E., Ruhl, V.E., Rodier, F., et al. (2009). A versatile viral system for expression and depletion of proteins in mammalian cells. PLoS One 4, e6529.
5. Chadeuf, G., Favre, D., Tessier, J., et al. (2000). Efficient recom-binant adeno-associated virus production by a stable rep-cap HeLa cell line correlates with adenovirus-induced amplification of the integrated rep-cap genome. J. Gene Med. 2, 260-268.
6. Chamberlain, J.S. (2002). Gene therapy of muscular dystrophy. Hum Mol Genet 11, 2355-2362. (Pubitemid 35174698)
7. Clark, K.R., Voulgaropoulou, F., Fraley, D.M., and Johnson, P.R. (1995). Cell lines for the production of recombinant adeno-associated virus. Hum. Gene Ther. 6, 1329-1341.
8. Clement, N., Knop, D.R., and Byrne, B.J. (2009). Large-scale adeno-associated viral vector production using a herpesvirus-based system enables manufacturing for clinical studies. Hum. Gene Ther. 20, 796-806.
9. Davidoff, A.M., Ng, C.Y., Sleep, S., et al. (2004). Purification of recombinant adeno-associated virus type 8 vectors by ion exchange chromatography generates clinical grade vector stock. J. Virol. Methods 121, 209-215. (Pubitemid 39295711)
10. Francois, A., Guilbaud, M., Awedikian, R., et al. (2005). The cellular TATA binding protein is required for rep-dependent replication of a minimal adeno-associated virus type 2 p5 element. J. Virol. 79, 11082-11094. (Pubitemid 41170649)
11. Gao, G., Qu, G., Burnham, M.S., et al. (2000). Purification of recombinant adeno-associated virus vectors by column chro-matography and its performance in vivo. Hum. Gene Ther. 11, 2079-2091.
12. Gao, G.P., Alvira, M.R., Wang, L., et al. (2002). Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc. Natl. Acad. Sci. U. S. A. 99, 11854-11859. (Pubitemid 34994488)
13. Im, D.S., and Muzyczka, N. (1990). The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity. Cell 61, 447-457.
14. Jiang, X.C., Qin, S., Qiao, C., et al. (2001). Apolipoprotein B secretion and atherosclerosis are decreased in mice with phos-pholipid-transfer protein deficiency. Nat. Med. 7, 847-852. (Pubitemid 32691641)
15. Kang, W., Wang, L., Harrell, H., et al. (2009). An efficient rHSV-based complementation system for the production of multiple rAAV vector serotypes. Gene Ther. 16, 229-239.
16. Kohlbrenner, E., Aslanidi, G., Nash, K., et al. (2005). Successful production of pseudotyped rAAV vectors using a modified baculovirus expression system. Mol. Ther. 12, 1217-1225. (Pubitemid 41723056)
17. Leonard, J.N., Ferstl, P., Delgado, A., and Schaffer, D.V. (2007). Enhanced preparation of adeno-associated viral vectors by using high hydrostatic pressure to selectively inactivate helper adenovirus. Biotechnol. Bioeng. 97, 1170-1179. (Pubitemid 47195314)
18. Li, W., Asokan, A., Wu, Z., et al. (2008). Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Mol. Ther. 16, 1252-1260. (Pubitemid 351866056)
19. Liu, X., Voulgaropoulou, F., Chen, R., et al. (2000). Selective Rep-Cap gene amplification as a mechanism for high-titer recom-binant AAV production from stable cell lines. Mol. Ther. 2, 394-403.
20. Lock, M., Alvira, M., Vandenberghe, L.H., et al. (2010). Rapid, simple and versatile manufacturing of recombinant adeno-associated virus vectors at scale. Hum. Gene Ther. 21, 1259-1271.
21. Maguire, A.M., High, K.A., Auricchio, A., et al. (2009). Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 374, 1597-1605.
22. Maguire, A.M., Simonelli, F., Pierce, E.A., et al. (2008). Safety and efficacy of gene transfer for Leber's congenital amaurosis. N. Engl. J. Med. 358, 2240-2248. (Pubitemid 351724453)
23. Maheshri, N., Koerber, J.T., Kaspar, B.K., and Schaffer, D.V. (2006). Directed evolution of adeno-associated virus yields enhanced gene delivery vectors. Nat. Biotechnol. 24, 198-204. (Pubitemid 43221704)
24. Margaritis, P., and High, K.A. (2010). Gene therapy in haemophilia-going for cure? Haemophilia 16 Suppl. 3, 24-28.
25. McCarty, D.M., Fu, H., Monahan, P.E., et al. (2003). Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther. 10, 2112-2118. (Pubitemid 37536760)
26. McDonell, M.W., Simon, M.N., and Studier, F.W. (1977). Analysis of restriction fragments of T7 DNA and determination of molecular weights by electrophoresis in neutral and alkaline gels. J. Mol. Biol. 110, 119-146. (Pubitemid 8034949)
27. Meghrous, J., Aucoin, M.G., Jacob, D., et al. (2005). Production of recombinant adeno-associated viral vectors using a baculo-virus/insect cell suspension culture system: from shake flasks to a 20-L bioreactor. Biotechnol. Prog. 21, 154-160. (Pubitemid 40218484)
28. Mendell, J.R., Campbell, K., Rodino-Klapac, L., et al. (2010a). Dystrophin immunity in Duchenne's muscular dystrophy. N. Engl. J. Med. 363, 1429-1437.
29. Mendell, J.R., Rodino-Klapac, L.R., Rosales-Quintero, X., et al. (2009). Limb-girdle muscular dystrophy type 2D gene therapy restores alpha-sarcoglycan and associated proteins. Ann. Neurol. 66, 290-297.
30. Mendell, J.R., Rodino-Klapac, L.R., Rosales, X.Q., et al. (2010b). Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol. 68, 629-638.
31. Nony, P., Tessier, J., Chadeuf, G., et al. (2001). Novel cis-acting replication element in the adeno-associated virus type 2 genome is involved in amplification of integrated rep-cap sequences. J. Virol. 75, 9991-9994. (Pubitemid 32900135)
32. Qiao, C., Li, J., Skold, A., et al. (2002a). Feasibility of generating adeno-associated virus packaging cell lines containing induc-ible adenovirus helper genes. J. Virol. 76, 1904-1913. (Pubitemid 34094637)
33. Qiao, C., Wang, B., Zhu, X., et al. (2002b). A novel gene expression control system and its use in stable, high-titer 293 cell-based adeno-associated virus packaging cell lines. J. Virol. 76, 13015-13027. (Pubitemid 35386985)
34. Schmidt, M., Afione, S., and Kotin, R.M. (2000). Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53. J. Virol. 74, 9441-9450.
35. Smith, R.H., Yang, L., and Kotin, R.M. (2008). Chromatography-based purification of adeno-associated virus. Methods Mol. Biol. 434, 37-54.
36. Suzuki, Y., Kagawa, N., Fujino, T., et al. (2005). A novel high-throughput (HTP) cloning strategy for site-directed designed chimeragenesis and mutation using the Gateway cloning system. Nucleic Acids Res. 33, e109.
37. Tessier, J., Chadeuf, G., Nony, P., et al. (2001). Characterization of adenovirus-induced inverted terminal repeat-independent amplification of integrated adeno-associated virus rep-cap sequences. J. Virol. 75, 375-383.
38. Urabe, M., Ding, C., and Kotin, R.M. (2002). Insect cells as a factory to produce adeno-associated virus type 2 vectors. Hum. Gene Ther. 13, 1935-1943. (Pubitemid 35341035)
39. Wang, B., Li, J., and Xiao, X. (2000). Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. Proc. Natl. Acad. Sci. U. S. A. 97, 13714-13719.
40. Wang, Z., Ma, H.I., Li, J., et al. (2003). Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther. 10, 2105-2111. (Pubitemid 37536759)
41. Watchko, J., O'Day, T., Wang, B., et al. (2002). Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. Hum. Gene Ther. 13, 1451-1460.
42. Wu, Z., Wu, X., Cao, H., et al. (2002). A novel and highly efficient production system for recombinant adeno-associated virus vector. Sci. China C Life Sci. 45, 96-104. (Pubitemid 34231380)
43. Xiao, X., Li, J., and Samulski, R.J. (1998). Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72, 2224-2232. (Pubitemid 28100780)
44. Yang, L., Jiang, J., Drouin, L.M., et al. (2009). A myocardium tropic adeno-associated virus (AAV) evolved by DNA shuffling and in vivo selection. Proc. Natl. Acad. Sci. U. S. A. 106, 3946-3951.
45. Yang, Q., Chen, F., and Trempe, J.P. (1994). Characterization of cell lines that inducibly express the adeno-associated virus Rep proteins. J. Virol. 68, 4847-4856.